Vaccine policymakers routinely ignore the safest and most effective strategies that can naturally strengthen your immunity to help you stay well or move through illness with fewer complications if you do get sick.For example, there are many far more effective ways to prevent the flu and other flu-like diseases, such as dietary interventions, making sure your vitamin D and gut flora are optimized, being more meticulous about washing your hands, getting enough exercise and sleep, and taking natural immune boosters like oil of oregano and garlic.But ignoring the obvious is not the worst of it.The vaccine industry is also ceaselessly working to figure out which propaganda strategy can most effectively lull concerned parents back to sleep and quit asking questions about safety.Such questions threaten that which is truly important to the vaccine industry: their profits. Sadly, vaccines DO come with potential side effects, and many parents are already grossly underinformed about such risks. Narcolepsy, for example, has yet again been confirmed as a vaccine-induced side effect from the European version of the 2009-2010 H1N1 swine flu vaccine that contained an oil in water adjuvant, ASO3.With such serious side effects at stake, should the government really be permitted to resort to what’s looking like outright fraud, in order to increase vaccination rates?
Flu Vaccine Shown to have Shockingly Low Effectiveness Rate
Propaganda scare tactics still do work, as demonstrated by the 25 percent uptick in 2012-2013 seasonal flu vaccine sales reported by Novartis.1 This despite the fact that not just one, but three recent studies published in the journal Eurosurveillance2, 3, 4 strongly challenge the claim that the influenza vaccine will protect you against the flu.According to CIDRAP:5“All three studies suggest that during the 2011-12 flu season, the vaccine provided modest protection at first, but its effectiveness dropped sharply after 3 or 4 months.A multicenter study by researchers in eight European countries indicated that overall vaccine effectiveness (VE) against influenza A/H3N2 in the first months of the season was 38%, but after mid-February it dropped to -1%.‘The concept that vaccine protection can be so short-lived provides a challenge for public health policy,’ says the British report.”